Biotechnology company developing engineered IgM antibodies for the treatment of cancer.
IGM Biosciences, Inc. is a pioneering biotechnology company specializing in the development of Immunoglobulin M (IgM) antibodies tailored for treating a spectrum of conditions including cancer, infectious diseases, autoimmune disorders, and inflammatory diseases.
Leading its innovative pipeline is IGM-2323, a bispecific IgM antibody currently advancing through Phase 2 clinical trials. This candidate targets relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). Additionally, the company is progressing IGM-8444, an IgM antibody in Phase 1 clinical trials aimed at treating various solid cancers.
IGM Biosciences is also developing IGM-7354, an anti-PD-L1 IgM antibody designed to address solid and hematologic malignancies. Further advancing its portfolio, the company is working on IGM-2644, a bispecific T cell engaging IgM antibody that targets CD38 and CD3 proteins for the treatment of multiple myeloma. Additionally, IGM-2537, another bispecific T cell engaging IgM antibody, is in development targeting CD123 and CD3 proteins for acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia.
Founded in 1993 and headquartered in Mountain View, California, IGM Biosciences, Inc. operates with a strategic collaboration and license agreement with Genzyme Corporation. This partnership supports the generation, development, manufacture, and commercialization of IgM antibodies, reinforcing IGM Biosciences' commitment to pioneering novel therapeutic solutions across diverse medical fields.